Rusfertide Earns FDA BTD for Erythrocytosis in Polycythemia Vera
Written by
Cancer Network
Published
0
comments
0
min
Results from the phase 3 VERIFY trial of rusfertide for erythrocytosis in patients with polycythemia vera led to the FDA decision.